Abstracts tagged "Access to care"

Abstract Number: 2615 • ACR Convergence 2025
The Cost of Complexity: Financial Toxicity in Rheumatic Disease, Cancer, and Their Intersection
Manush Sondhi¹, Bhavik Bansal², Hemant Khandelia¹, Jiha Lee³, Sebastian E Sattui⁴, Siddharth Singh⁵ and Namrata Singh⁶, ¹University of Washington, Seattle, WA, ²UT Southwestern Medical Center, Dallas, ³University of Michigan, Ann Arbor, MI, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵University of California San Diego, San Diego, CA, ⁶University of Washington, Bellevue, WA
Background/Purpose: Financial toxicity (FT) is the financial burden of accessing health care, well known in cancer and increasingly seen in rheumatic disease (RD). We compared…
Abstract Number: 1982 • ACR Convergence 2025
Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
Kuan-Tung Lin¹, Yue Hao², Mai Abdelnabi² and Wai-Hang Jackie Lam², ¹North East Medical Services, San Mateo, CA, ²North East Medical Services, San Francisco, CA
Background/Purpose: Patients with rheumatologic conditions who are on immunosuppressive therapy face an elevated risk of pneumococcal infections, particularly those in medically underserved populations. Per ACR…
Abstract Number: 1689 • ACR Convergence 2025
Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support
Kimberly Cabrera¹, Priscilla Calvache², Lillian Mendez³, Giselle Morales⁴ and Jillian Rose-Smith², ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, ³Patient Advocate, Carteret, NJ, ⁴Hospital for Special Surgery, Glendale, NY
Background/Purpose: SLE is a life-threatening autoimmune disease that disproportionately affects African American (AA), Hispanic/Latino, & Asian populations. These communities experience serious health disparities, including more…
Abstract Number: 1055 • ACR Convergence 2025
The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use
Antara Dattagupta¹, Colin Diffie² and Sana Cheema², ¹Washington University in St. Louis, St. Louis, MO, ²Washington University in St. Louis, St. Louis
Background/Purpose: High-cost biologic therapies are integral to the management of rheumatoid arthritis (RA), yet access to these agents may be influenced by insurance type, particularly…
Abstract Number: 0205 • ACR Convergence 2025
Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
Laura Mas Sanchez¹, ELENA GRAU GARCIA², Carlos Valera Ribera³, Pablo Muñoz-Martínez⁴, Daniel Ramos Castro⁵, Alba Maria Torrat Noves⁶, Belen Villanueva Manes⁷, Iago Alcántara Álvarez⁸, Miguel Simeo Vinaixa⁹, Andres Perez Hurtado¹⁰ and José Andrés Román Ivorra¹¹, ¹Hospital Universitari i Politecnic La Fe, València, Spain, ²HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Hospital Universitario Doctor Peset, València, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital La Fe, València, Spain, ⁸Hospital Universitari i Politénic La Fe, València, Spain, ⁹Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: In 2023, Spain approved the inactivated varicella zoster virus (VZV) vaccine in individuals over 50 years of age with immunosuppressive conditions, including rheumatology patients…
Abstract Number: 2586 • ACR Convergence 2025
Estimated Carrier Prevalence of HLA-B*58:01 Across Diverse Populations in the US and Globally
Qiping Xu¹, Joan Bathon² and Yiming Luo², ¹Mayo Clinic, Mankato, ²Columbia University, NEW YORK, NY
Background/Purpose: The HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions. The 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout…
Abstract Number: 1981 • ACR Convergence 2025
High Patient Satisfaction with a Medication Education Program: Program to Understand Rheumatology Medications with Pharmacist Led Education
Kami Roake¹, Natalie Morlan¹, Stephanie Lim¹, Jennifer Giles¹, Anthony Minjarez², Grant Cannon³, Nadia Grant⁴, Vivianne Allsop⁵, Miranda Jensen¹, Madeline O'Sullivan¹, Christopher Ching¹, Michael Bessen¹, Javier Rios⁶ and Jessica A. Walsh⁷, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA, Salt Lake City, UT, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴University of Utah, Salt Lake City, ⁵University of Utah, South Jordan, UT, ⁶University of Utah Health, Salt Lake City, UT, ⁷Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT
Background/Purpose: Patient education is critical for managing rheumatic diseases. Rheumatology clinic pharmacists are well-positioned to assess and address gaps in patients’ understanding of their medications.…
Abstract Number: 1660 • ACR Convergence 2025
Digital Psychological Support for Inflammatory Rheumatic Diseases: A Randomized Clinical Trial
Johannes Knitza¹, Julia Kraus², Martin Krusche³, Isabell Haase³, Philipp Klemm⁴, Axel Hueber⁵, Pfeil Alexander⁶, Ulrich Drott⁷, Sebastian Kuhn⁸ and Jan Philipp Klein⁹, ¹Institute for Digital Medicine, University Hospital Gießen-Marburg, Philipps University, Marburg, Germany, ²Vila Health, Berlin, Germany, ³Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁴Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ⁵Klinikum Nuernberg, Nuernberg, Germany, ⁶Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany, ⁷Deutsches Endokrinologisches Versorgungszentrum, Frankfurt, Germany, ⁸Institute for Digital Medicine, University Hospital of Giessen and Marburg, Philipps University Marburg, Marburg, Germany, ⁹Department of Psychiatry, Psychosomatics and Psychotherapy, University of Lübeck, Lübeck, Germany
Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) frequently experience psychological distress, however access to psychological support remains limited. The aim of this trial (DRKS identifier:…
Abstract Number: 1039 • ACR Convergence 2025
CAR-T Therapy in Rheumatoid Arthritis: A Health Systems Analysis of Cost and Global Equity
Asrith Reddy Gandu¹ and Kolluri Prathyusha², ¹Davao medical school foundation, Hyderabad, India, ²University of delaware, Newark, DE
Background/Purpose: Refractory rheumatoid arthritis (RA) affects 30–40% of patients with limited therapeutic options and high disability burdens. Although CAR‑T therapy has been transformative in oncology…
Abstract Number: 0196 • ACR Convergence 2025
Increasing Timely Rheumatology Evaluation for High Risk Lupus Patients
Steven Taylor¹ and Elena Weinstein², ¹University of Colorado, Denver, CO, ²University of Colorado, Englewood, CO
Background/Purpose: The rheumatology workforce shortage presents many challenges to the delivery of rheumatology care. Improving timely access to rheumatology for patients with life or organ…
Abstract Number: 2558 • ACR Convergence 2025
Impact of Social Determinants of Health on Patient Perceptions of Home Infusion Therapy in the Treatment of Rheumatologic Conditions
Leslie Myers¹, Elizabeth Neal², Edward O'Bryan¹, Michele Way³ and Timothy Walton¹, ¹CSI Pharmacy, Nash, ²CSI Pharmacy, Nash, TX, ³CSI Pharmacy, Olathe, KS
Background/Purpose: Home infusion therapy is an established alternative site of care for patients requiring administration of infusion medications through a needle or catheter. Supported by…
Abstract Number: 1975 • ACR Convergence 2025
Baseline QTc Screening and Monitoring Among SARD Patients with High Cardiovascular Risks on Hydroxychloroquine Based on 2021 ACR Consensus: A Quality Improvement Project
Cristine Kuzhuppilly Arcilla¹, Gabriel Kirsch², Gurjit Kaeley³ and Myint Thway⁴, ¹University of Florida Jacksonville, Jacksonville, FL, ²University of Florida - Jacksonville, Jacksonville, FL, ³UF COM-J, Ponte Vedra Beach, FL, ⁴UF Jacksonville, ponte vedra, FL
Background/Purpose: In 2017, FDA approved warnings regarding fatal cardiac effects such as cardiomyopathy, torsades de pointes, and QTc prolongation related to both acute and chronic…
Abstract Number: 1295 • ACR Convergence 2025
Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America
Martha Rodriguez¹, Ekemini Ogbu², Ashley Danguecan³, Marietta De Guzman⁴, Alexandra Theisen⁵, Lawrence Ng⁶, Andrea Knight³ and Ryann Kammeyer⁷, ¹Riley Hospital For Children at Indiana University, Indianapolis, IN, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Hospital for Sick Children, Toronto, ON, Canada, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Arkansas, Little Rock, AR, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷University of Colorado, Denver, CO
Background/Purpose: Neuropsychiatric involvement in Systemic Lupus Erythematosus (NPSLE) is a major cause of morbidity and mortality, particularly among children who are still developing neurologically. Despite…
Abstract Number: 1013 • ACR Convergence 2025
All roads lead to Rheum? Modeling scenarios of new patients-to-pediatric rheumatologist ratios in different US states
Gabriela Accetta Rojas¹, Evan Mulvihill², Salma Siddique¹ and Annemarie Brescia¹, ¹Nemours Children's Hospital of Delaware, Wilmington, DE, ²Nemours/A.I.duPont Hospital for Children, Wilmington, DE
Background/Purpose: Rheumatology is among the pediatric subspecialties with the lowest workforce density in the US1. Initial management of most of the pediatric rheumatologic conditions relies…
Abstract Number: 0192 • ACR Convergence 2025
Digital Empowerment on Hold: Adoption Gaps in Prescribable Digital Health Applications – A National Cross-Sectional Study from Germany
Phillip Kremer¹, Daniel Fink², Harriet Morf³, Hannah Labinsky⁴, Karolina Gente⁵, Peer Aries⁶, Martin Krusche¹, Sebastian Kuhn⁷, Axel Hueber⁸ and Johannes Knitza⁹, ¹Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ²Rheumazentrum Mittelhessen, Bad Endbach, Germany, ³Department of Medicine ³ - Rheumatology & Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁴University Hospital of Wuerzburg, Würzburg, Germany, ⁵Department of Internal Medicine V - Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Baden-Wurttemberg, Germany, ⁶Department of Rheumatology, Immunologikum, Hamburg, Germany, ⁷Institute for Digital Medicine, University Hospital of Giessen and Marburg, Philipps University Marburg, Marburg, Germany, ⁸Klinikum Nuernberg, Nuernberg, Germany, ⁹Institute for Digital Medicine, University Hospital Gießen-Marburg, Philipps University, Marburg, Germany
Background/Purpose: Rheumatic and musculoskeletal diseases (RMDs) are chronic conditions that require complex, multidisciplinary care. Since 2020, digital health applications (DiGAs) have been available for prescription…

1
2
3
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].